Skip to content
Screener

iRadimed IRMD Q3 2026 earnings

Reported October 30, 2026 · Before market open

Revenue$24.2MBeat by $733.3K
EPS$0.55In line
Revenue estimate$23.5M
EPS estimate$0.55
“We are pleased to report record revenue of $24.2 million for the third quarter, driven by the continued successful launch of our new 3870 MR IV pump. As our manufacturing team gains experience with the new platform while at the same time greatly ramping up production, we began realizing the efficiencies we anticipated with gross margin improving sequentially as expected. Quarterly bookings also set new records, driven by another record number of monitor units being booked and a 45% year-over-year increase in domestic pump channels booked. Of special note is that over 70% of pump bookings in the quarter were for our 'quad stack' configuration of four pumps on a single IV pole, as customers continue to accelerate their replacement of our older model and standardize on this setup which is a doubling of pump channels previously available at each MRI. With record bookings and rapidly building 3870 momentum, we believe we are well positioned for a strong finish to the year”
Roger Susi

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$24.2M+14.2%
Gross profit$18.5M+11.9%
Operating income$8.1M+19.1%
Net income$6.5M+16.7%
EPS (diluted)$0.51+18.6%

Balance sheet

See full
Cash & equivalents$63.3M+12.0%
Total equity$106.5M+8.2%
Total assets$121.1M+5.5%

Cash flow

See full
Operating cash flow$7.0M+0.2%
CapEx$130.0K-88.6%
Free cash flow$6.9M+17.4%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$1.1B+12.8%
P/E45.7×-0.2×
P/S12.3×+0.2×

Profitability

See full
Gross margin75.5%-1.6pp
Operating margin32.3%+1.4pp
Net margin26.8%+0.5pp
FCF margin29.3%+10.9pp

Returns & leverage

See full
Return on equity23.4%+0.1pp
Current ratio9×+2.4×

Segments

By product

See full
MRI Compatible IV Infusion Pumps$8.7M—
MRI Compatible Patient Vital Signs Monitoring Systems$8.0M—
Disposables$5.0M—
Services and other$1.2M—
Amortization of extended maintenance agreements$801.0K—

FAQ

When did iRadimed report Q3 2026 earnings?
iRadimed (IRMD) reported Q3 2026 earnings on October 30, 2026 before market open.
What were iRadimed's Q3 2026 revenue and EPS?
iRadimed reported revenue of $24.2M and eps of $0.55 for Q3 2026.
Did iRadimed beat estimates in Q3 2026?
Revenue beat the consensus estimate of $23.5M by $733.3K. EPS beat the consensus estimate of $0.55 by $0.00.
How did iRadimed's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 14.1% from $21.2M a year earlier and eps grew 17.0% from $0.47.
Where can I find iRadimed's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-068454) and the 10-Q periodic report (0001628280-26-068576) directly on SEC EDGAR. The filing index links above go to sec.gov.